The HCV polymerase is an attractive target for the development of new and specific anti-HCV drugs. Herein, the characterization of the inhibitory effect of 2′-C-Methyl-Cytidine shows that it is a potent inhibitor of both genotype 1b and 1a HCV replicon replication, both of laboratory-optimized as well as of NS5B clinical isolates-chimera replicons. The corresponding 5′-triphosphate derivative is a potent inhibitor of native HCV replicase isolated from replicon cells and of the recombinant genotype 1b and 1a HCV polymerase-mediated RNA synthesis. Resistance to 2′-C-Methyl-Cytidine was mapped to amino acid substitution S282T in the NS5B coding region. Cross-resistance was observed to 2′-C-Methyl-Adenosine but not to interferon α-2a, to non-nucleoside HCV polymerase inhibitors or to R1479, a new and potent nucleoside inhibitor of NS5B polymerase. In vitro studies mapped resistance to R1479 to amino acid substitutions S96T and S96T/N142T of the NS5B polymerase. These mutations did not confer resistance to 2-C-Methyl-Cytidine, thus confirming the lack of cross-resistance between these two HCV inhibitors. These data will allow the optimization of new polymerase inhibitors and their use in combination therapy.
Introduction
Hepatitis C virus (HCV), a positive strand RNA virus, is a member of the Hepacivirus genus, in the Flaviviridae family, and is one of the leading causes of liver disease worldwide. It is estimated that over 170 million individuals are infected worldwide with HCV (Wasley and Alter, 2000) . The virus has been classified into 6 major genotypes (1-6) showing more than 30% divergence among them. Each genotype contains a series of more closely related subtypes which show a 20-25% divergence in nucleotide sequences (Simmonds, 2004) . Acute infection with HCV develops into chronic infection in approximately 80% of individuals, and chronic hepatitis can, in turn, progress to cirrhosis and hepatocellular carcinoma. The current treatment for chronic hepatitis C is pegylated interferon α (IFN-α) in combination with ribavirin (Fried et al., 2002; Hadziyannis et al., 2004; Manns et al., 2001 ) that results in approximately 50% of a sustained viral response (SVR) for patients infected with a genotype 1 virus and approximately 80% SVR for patients infected by genotype 2 or genotype 3 viruses. However, the treatment is often poorly tolerated, limiting its use in some patients and emphasizing the urgent need for more effective and HCVspecific antiviral therapies.
The HCV polymerase is an essential enzyme for virus RNA replication and represents an attractive therapeutic target. With the advent of the HCV replicon cell culture system, there have been extensive developments around the discovery of new HCV polymerase inhibitors, both nucleoside Migliaccio et al., 2003; Olsen et al., 2004) and non-nucleoside inhibitors (Beaulieu et al., 2004a-c; Chan et al., 2004a,b; Dhanak et al., 2002) . While new HCV inhibitors have yet to be approved for the treatment of HCV-infected individuals, HCV polymerase inhibitor NM283, a valine ester prodrug of NM107, 2′-C-Methyl-Cytidine (2′-C-Me-C) is currently in phase II Virology 351 (2006) 349 -359 www.elsevier.com/locate/yviro clinical trials (Godofsky et al., 2004; Pierra et al., 2005) . Recently, a new potent nucleoside HCV polymerase inhibitor, R1479 (4′-Azido-Cytidine), which has been selected for further clinical development for the treatment of HCV infection has been described (Klumpp et al., 2006) . The high genetic heterogeneity of HCV, due to the error-prone nature of its RNA-dependent RNA polymerase, represents an opportunity for the virus to evade antiviral treatment. The development of successful therapies based on inhibitors targeting viral enzymes requires an understanding of the nature of resistant HCV variants likely to be selected upon treatment. This will help in the design and selection of new inhibitors with different resistance profiles with the aim of delaying the selection of resistant variants, thus resulting in more efficacious therapies. Previous studies have demonstrated the possibility of selecting HCV-resistant variants against different antiviral agents using the HCV subgenomic replicon system Nguyen et al., 2003; Tomei et al., 2003 Tomei et al., , 2004 . Here, we have used the HCV subgenomic replicon to select and characterize HCV-resistant variants to 2′-C-Me-C, and to R1479, two potent HCV polymerase inhibitors. In this study, we show that unique amino acid substitutions in the NS5B gene are responsible for resistance to 2′-C-Me-C or to R1479. These findings confirm the lack of cross-resistance between these polymerase inhibitors and will help in the design of future combination therapies.
Results

2′-C-Methyl-Cytidine inhibits genotype 1b and genotype 1a HCV replication
To determine the activity of 2′-C-Me-C ( Fig. 1 ) on HCV replicon replication, the inhibitor was tested using the genotype 1b strain Con1 and genotype 1a strain H77 stable HCV subgenomic replicons and was measured as a reduction of reporter renilla luciferase levels after 72 h of treatment. 2′-C-Me-C inhibited both the genotype 1b strain Con1 replicon, with an IC 50 value of 1.1 μM (Klumpp et al., 2006) and the genotype 1a strain H77 replicon with an IC 50 value of 0.3 μM (Table 1) . No cytotoxicity, as measured by WST-1, was observed up to 100 μM for genotype 1b (Klumpp et al., 2006) or for genotype 1a (Table 1) . The inhibitory activity of 2′-C-Me-C was also evaluated on transient replicons containing the NS5B coding region from genotype 1b and 1a clinical isolates (see Materials and methods), showing similar potency than for the laboratory-optimized Con1 and H77 replicons ( Table 2) .
The inhibition potency of 2′-C-Me-CTP on the RdRp activity of recombinant NS5B proteins was confirmed using both genotype 1b (NS5B570-BK and NS5B570-Con1) and genotype 1a (NS5B570-H77) enzymes (Table 3) . Genotype 1a NS5B570-H77 polymerase showed similar sensitivity to the compound Fig. 1 . Chemical structures of (A) 2′-C-Methyl-Cytidine, (B) 2′-C-Methyl-Adenosine, (C) 3′-deoxy-Cytidine, (D) R1479, (E) Benzo-1, 2, 4-thiadiazine (NNI-1), and (F) Thiophene-2-carboxylic acid (NNI-2). compared to the genotype 1b polymerases. The IC 50 values determined under PI (Poly I) assay conditions, which only drive the incorporation of cytidine monophosphate (CMP) into the RNA product, were 3-fold to 8-fold lower than the IC 50 values determined under genotype 1a assay conditions, which drive the incorporation of all four nucleotide monophosphates. This shift in potency was consistent with a specific inhibition of CMP incorporation by 2′-C-Me-CTP (Klumpp et al., 2006) .
Additive inhibition of HCV replication by 2′-C-Me-C in combination with IFN-α
In order to assess the activity of 2′-C-Me-C in combination with IFN-α, in vitro combination studies were carried out as described in Materials and methods. The fractions of the inhibitory concentrations (FIC values) were derived from the calculation of 90% inhibition of the renilla luciferase reporter across checkerboard titrations of both inhibitors after 72 h incubation (0.04 to 10 IU/ml for IFN-α and 0.04 to 10 μM for 2′-C-Me-C). The combination index (FIC A + FIC B ) for 2′-C-Me-C in combination with IFN-α was calculated to be between 0.5 and 1 (additive line), indicating that this combination inhibits the replicon RNA replication in an additive manner (Fig. 2) . The data were also examined using the Pritchard and Shipman's 3-D model (MacSynergy II) (Prichard and Shipman, 1990) , where the nature of the combination is examined across the whole range of inhibitory concentrations used (data not shown). Consistent results were obtained using both methods.
2′-C-Me-C can clear the HCV replicon RNA
To determine the kinetics of the subgenomic HCV replicon inhibition by 2′-C-Me-C, HCV replicon cells were cultured in the presence of 8 μM of inhibitor for 13 days and in the absence of neomycin selection (replicon clearance phase) (Fig. 3) . During this phase, Huh-7 cells were able to proliferate even in the absence of active replicon replication. During the rebound phase, the inhibitor was removed, and cells were cultured for a further 15 days in culture medium containing 0.25 mg/ml of neomycin. HCV RNA levels were monitored every 3 days as described in Materials and methods and remained constant throughout the replicon clearance phase in the untreated cells. During the rebound phase, the addition of neomycin had no effect on the level of HCV RNA. In the presence of 8 μM of inhibitor and after 10 days, the HCV RNA level dropped a maximum of 3.8 logs. After 13 days, the HCV RNA had a The IC 50 values and standard deviation were determined from at least 3 independent experiments under either genotype 1a or PI assay conditions, as described in Materials and methods. modest rebound of 0.8 logs. The very low levels of replicon RNA observed after day 8 could be due to the detection of residual RNAs that are not fully replication competent or could be a reflection of the presence of small levels of replicons able to replicate in the presence of inhibitor. However, the HCV subgenomic RNA replication was inhibited to levels that were not sufficient enough to allow the survival of the cells even in the presence of low concentrations of neomycin (0.25 mg/ml).
Selection and characterization of replicons resistant to 2′-C-Me-C
Replicon cellular clones resistant to 2′-C-Me-C were obtained after long-term culture in the presence of increasing concentrations of 2′-C-Me-C starting at 6 μM and up to 24 μM. All clones contained similar levels of HCV replicon RNA as determined by quantitative kinetic PCR (data not shown). Four cellular clones were further characterized by direct sequencing of PCR products spanning the entire NS3 to NS5B regions, as well as by determining their susceptibility to different classes of HCV inhibitors. While the mean 2′-C-Me-C IC 50 value for the untreated cells was 0.8 ± 0.1 μM and for clone 9 was 1.1 μM, three replicon cellular clones (clones 1, 5, and 10) showed reduced susceptibility to 2′-CMe-C (Table 4) . Cross-resistance was observed to 2′-C-Me-A (Fig. 1, Table 4 ), whereas no cross-resistance was observed to nonnucleoside inhibitor benzo-1, 2, 4-thiadiazine derivative (NNI-1) (Fig. 1, Table 4 ) or to IFN-α (Table 4 ). Sequencing analysis of the entire non-structural region, spanning NS3 to NS5B revealed only one common mutation in the NS5B polymerase gene at position 282, changing a serine to a threonine in all three resistant clones and not in sensitive cells. Clones 5 and 10 had one additional mutation, either K81N or M573R, respectively (Table 4) . Sequencing analysis of 26 molecular clones of replicon cellular clone 10 showed that mutations S282T and M573R coexisted in all genomes (data not shown).
To confirm that the observed resistant phenotype was not due to a cellular effect, cytoplasmic replicase complexes (CRCs) from cells carrying wild type (WT) or S282T replicon obtained as described in Materials and methods were isolated and used to measure the inhibition of RNA synthesis activity by 2′-C-Me-CTP. As a control, the relative expression levels of NS5B in the WT or S282T CRCs were determined by Western blotting using recombinant NS5B570-BK as a reference. The NS5B levels in WT and S282T CRCs were derived from the NS5B band volumes of loading 0.625 μl of CRC, which were within the linear range of band volumes of recombinant NS5B570-BK titrations ( Fig. 4A lane a, and data not shown). The NS5B protein levels in WT and S282T replicase complexes were 19.3 and 18.4 ng/μl (5 × 10 5 cells equivalent) of membrane fraction respectively, suggesting that S282T mutation does not cause a measurable change in the overall stability and steady-state level of the NS5B protein in stably transfected replicon cells. Under the in vitro replicase assay conditions, the WT and S282T replicases showed similar time course kinetics with RNA product formation increasing linearly with reaction time up to 90 and 120 min, respectively (data not shown). Therefore, 90-min reaction time was chosen as the condition for measuring inhibitory effects of compounds on both replicases. S282T replicase had a reduced susceptibility to the inhibition by 2′-C-Me-CTP with a mean IC 50 value of 12.1 ± 4.6 μM, which is 60-fold higher than that of the WT replicase (0.20 ± 0.17 μM). However, both WT and S282T replicases showed similar sensitivity to 3′-dCTP ( Fig. 1, Fig. 4B and Table 5 ) and to R1479-TP (Klumpp et al., 2006) . These results showed that resistance to 2′-C-Me-C was indeed due to a viral component and likely correlated with the presence of the S282T mutation in the polymerase gene. Table 4 Characterization of replicon clones after selection with 2′-C-Me-C Cellular clones 
Characterization of mutations S282T and M573R in the NS5B polymerase
To confirm the role of the NS5B amino acid residue S282 in resistance to 2′-C-Me-C, mutation S282T was engineered into the WT transient genotype 1b replicon by site directed mutagenesis. Replicon RNAs were transiently transfected into cured Huh-7 cells and their replication levels and susceptibility to 2′-C-Me-C, 2′-CMe-A and to a thiophene carboxylic acid derivative (nonnucleoside inhibitor NNI-2, Fig. 1 ) were determined. The transient replication capacity of S282T mutant was impaired, with a replication capacity of 22% compared to the WT transient replicon (Table 6 ) as previously described . Mutation S282T conferred resistance to 2′-C-Me-C, with a 30-fold IC 50 shift (Fig. 5, Table 6 ), showing cross-resistance to 2′-C-Me-A, as previously described . Importantly, it did not confer resistance to R1479 (Klumpp et al., 2006) or to NNI-2 (Table 6) .
To determine the role of amino acid substitution M573R, single mutant M573R and double mutant S282T/M573R were engineered in the Con1 transient replicon. Single mutant M573R did not confer resistance to 2′-C-Me-C or to other HCV polymerase inhibitors nor did it confer a significant replication advantage to the wild type or S282T replicon in the absence or presence of 2′-C-Me-C (Table 6) .
To correlate the decrease in inhibition potency of 2′-C-Me-C on the resistant replicon containing the S282T mutation in the NS5B polymerase, the single mutant S282T recombinant enzyme was engineered in the NS5B570-Con1 backbone and tested in the polymerase assay. The inhibitory potency of 2′-CMe-CTP on NS5B570-Con1-S282T was reduced by 111-fold. In contrast, it did not confer resistance to 3′-dCTP (Table 7) or to R1479-TP (Klumpp et al., 2006) , confirming the specific role of S282T mutation in resistance to 2′-C-Me-C. Kinetic analysis of NS5B570-Con1-S282T showed a 2-fold increase in V max app and a 2-fold decrease in K m app (CTP) compared to NS5B570-Con1, leading to a 4-fold increase in enzyme efficiency (V max app /K m app (CTP)) of the S282T mutant over wild type (data not shown).
Selection and characterization of replicons resistant to R1479 confirms lack of cross resistance with 2′-C-Me-C
We have recently selected replicons resistant to R1479 through the sequential passage of cell line 2209-23 in the presence of increasing concentrations of R1479, as detailed in Materials and methods. Replicon cells selected in the presence of 60 μM R1479 showed a decrease in sensitivity to the inhibitor of more than 50-fold (mean IC 50 values ranged from 20.8 ± 2.3 μM to 56 ± 0.8 μM) compared to the untreated replicon cells (Table  8) . Direct sequencing of PCR products from replicon cells isolated after 37, 39, 41, and 50 passages in the presence of 60 μM of R1479 showed amino acid substitutions at residues 96 and 142 of the polymerase, which were not present in untreated cells from passage 41 (as demonstrated by direct sequencing of PCR products as well as by sequencing of 10 molecular clones). The mean IC 50 values and standard deviation were determined from at least 2 independent experiments. Table 6 S282T confers resistance to 2′-C-Me-C and 2′-C-Me-A and not to R1479 or to thiophene-2-carboxylic acid derivative (NNI-2) The IC 50 values and standard deviation were determined under genotype 1b assay conditions, as described in Materials and methods from at least two independent experiments.
Sequencing the NS5B region of 30 molecular clones from passage 39 treated cells showed that amino acid substitutions S96T and N142T co-existed in 22 out of the 30 clones (73.3%).
Single amino acid substitution S96T was observed in three clones (10%), whereas single amino acid substitution N142T was observed in one clone (3.3%). Four clones (13.2%) contained wild type residues at these two positions.
To determine the role of the observed NS5B amino acid substitutions, either the single amino acid substitutions S96T, N142T or the double amino acid substitution S96T/N142T were engineered into the transient GT 1b Con1 replicon by site-directed mutagenesis. The level of replication and sensitivity to R1479 and to 2′-C-Me-C were determined (Table 9 , Fig. 6 ). Mutant replicon S96T showed very low replication capacity (4% compared to the wild type), whereas single mutant N142T showed replication levels similar to the wild type. Double mutant S96T/N142T also showed a low level of replication (5%) compared to the wild type Con1 transient replicon, similar to that of single mutant S96T ( Table 9 ). The mean IC 50 value for R1479 using the wild type transient Con1 replicon was 1.96 ± 0.14 μM. A 4-to 5-fold reduction in sensitivity to R1479 (but not to 2′-C-Me-C) was observed for mutant S96T and for double mutant S96T/ N142T with IC 50 values of 8.2 ± 0.66 μM and 10.4 ± 1.4 μM respectively. No change in sensitivity to R1479 was observed for mutant N142T compared to the wild type transient replicon (Table 9) .
Discussion
HCV genotypes 1a and 1b are the most prevalent worldwide and the most difficult to treat with the current therapy (Fried et al., 2002; Hadziyannis et al., 2004; Manns et al., 2001; Simmonds, 2004) . This highlights the importance of developing new antiviral compounds able to target different genotypes. In this study, we have characterized and demonstrated for the first time that 2′-CMe-C is a potent inhibitor of genotype 1b and genotype 1a RNA HCV replicon replication, both of laboratory optimized and of replicons containing the NS5B derived from clinical isolates. NM-283, a prodrug of 2′-C-Me-C, is currently in phase II clinical development for the treatment of chronic hepatitis C. Given the limited efficacy of the current treatment, especially for individuals infected with a genotype 1 virus, IFN-α therapy in combination with new inhibitors targeting the virus is likely to ensure a more successful outcome for patients. To that effect, we demonstrated that 2′-C-Me-C in combination with IFN-α inhibits replicon replication in an additive manner. Therefore, the use of 2′-C-Me-C with IFN-α could be an adequate combination for a successful outcome for infected patients. Interestingly, upon prolonged exposure to high concentrations of 2′-C-Me-C, replicon RNA replication in stably transfected Huh-7 cells was reduced to such level that the cells were no longer able to proliferate in the presence of neomycin selective pressure. Very low levels of replicon RNA were observed after day 8 that could be due to the detection of residual RNAs that are not fully replication competent or due to a small level of replicons able to replicate in the presence of inhibitor. However, prolonged and stable replication of the HCV subgenomic RNA replicon was not observed after adding a low concentration of neomycin in the culture medium, suggesting that even if the observed modest rebound observed at day 13 was due to the detection of active replicating replicons, it was not sufficient b Sequencing (both direct PCR sequencing and sequence of 10 molecular clones) spanned amino acid residues 1-591.
c Direct PCR sequencing analysis spanned amino acid residues 1-330 of the NS5B polymerase.
d Sequencing (both direct PCR sequencing and sequence of 30 molecular clones) spanned amino acid residues 1-591.
e ND, not determined. f Direct PCR sequencing spanned amino acid residues 1-236 of the NS5B polymerase.
g Direct PCR sequencing spanned amino acid residues 1-591. Table 9 Resistance profile for R1479 shows lack of cross resistance to 2′-C-Me-C enough to allow the survival of the cells. Importantly, after similar studies using non-nucleoside inhibitors such as benzothiadiazines or thiophene-2-carboxylic acid derivatives, the replicon was not cleared from the transfected Huh-7 cells, but rather drug-resistant replicon variants were selected (Le Pogam et al., unpublished results). These results suggest an increased difficulty in the selection of replicon variants resistant to 2′-C-Me-C compared to nonnucleoside polymerase inhibitors. Despite these findings and after prolonged exposure to increasing concentrations of 2′-C-Me-C, replicons highly resistant to 2′-C-Me-C, containing amino acid substitution S282T in the NS5B coding region, were selected and replicated to similar levels as the WT replicon. This amino acid substitution was first selected in the presence of 2′-C-Me-A and characterized by Migliaccio et al. (2003) . The mechanism of resistance to 2′-C-Me nucleosides was shown to occur through the reduced affinity of the mutant enzyme for the inhibitor . Interestingly transient HCV replicons containing S282T mutant polymerase showed a reduced replication capacity compared to the WT transient replicon, in agreement with previous reports (Ludmerer et al., 2005; Migliaccio et al., 2003) . This discrepancy could be due to compensatory mutations in the NS5B protein or in other non-structural proteins. Indeed, two of the clones described in this study contained mutations S282T in combination with either T81P or M573R. A recent study using a transient replicon system to characterize activity from replicons containing NS5B from clinical isolates has shown that the introduction of the S282T mutation in those NS5B genes inhibited dramatically their level of replication, demonstrating that none of the tested NS5B polymerases carried intrinsic compensatory mutations (Ludmerer et al., 2005) . Interestingly, mutation at residue T81 was observed among the analyzed samples, whereas residue M573 was conserved among them. Our data show that mutation M573R does not confer a replication advantage to the replicon RNA either alone or in combination with S282T nor does it confer resistance to 2′-C-Me-C. The presence of M573R in the NS5B coding region may be due to a random selection and may have been maintained in the quasispecies possibly due to the fact that it replicates similarly to the wild type replicon. Characterization of the role of other viral regions isolated from infected patients in combination with the mutant S282T should allow a better understanding of the replication fitness of this particular resistant mutant and address whether its intrinsic low replication level could be compensated for in natural isolates. In the mean time, such compensatory mutations remain to be identified.
We have recently described a new nucleoside analog, R1479, which is a potent HCV polymerase inhibitor and that has been selected for further clinical development for the treatment of HCV infection. Given that future therapies for the treatment of this infection may involve the combination of antivirals, we investigated the possible cross-resistance between 2′-C-Me-C and R1479. To this effect, we have shown that amino acid substitution S282T does not affect the potency of R1479 (Klumpp et al., 2006) . Studies herein to characterize resistance to R1479 show the selection of amino acid substitutions S96T and N142T of the NS5B coding sequence. Amino acid substitution S96T alone or in combination with N142T conferred resistance to R1479 but not to 2′-C-Me-C, further confirming the lack of cross-resistance between these two inhibitors. Interestingly, most of the R1479-resistant replicon molecular clones analyzed showed the presence of amino acid substitutions S96T and N142T in combination. The replication levels of transient replicons containing either S96T or S96T and N142T were very low (4% to 5% of the WT). However, amino acid substitution N142T, which replicates at levels similar to those of WT, did not confer resistance to R1479 nor did it rescue the replication levels of the mutant S96T when in combination. Thus, the basis for co-selection of N142T is unclear at this point. Amino acid positions 96 and 142 are outside of the HCV polymerase active site and may be involved in primer/template binding (Bressanelli et al., 1999) . Sequence analysis across HCV genotypes from the public database shows a high level of conservation for both of these amino acid residues.
In summary, we showed here that the mutation S282T can be selected by passaging HCV replicon cells in the presence of 2′-CMe-C and confers resistance to 2′-C-Me-C. While mutation S282T conferred cross-resistance to 2′-C-Me-A and to 2′-C-Me-G, as previously reported , it did not confer resistance to another cytidine analog (4′-Azido-Cytidine, R1479) or to non-nucleoside polymerase inhibitors benzothiadiazine and thiophene-2-carboxylic acid derivatives. Indeed S282T transient replicon showed a slight increased susceptibility to R1479 (Klumpp et al., 2006) . Likewise, amino acid substitution S96T alone or in combination with N142T confers resistance to R1479 but not to 2′-C-Me-C. These data support further investigations into the potential clinical benefit of combinations of R1479, 2′-C-Me-C, nonnucleoside inhibitors and IFN-α. The clinical significance of the resistance mutations identified in this study is currently unknown, pending sequence analysis of HCV samples from HCV-infected individuals treated with these novel antiviral agents.
Materials and methods
Construction of plasmids
The genotype 1b Con1 and genotype 1a H77 HCV subgenomic replicons used in this study are based on the adapted bicistronic HCV subgenomic replicon constructs as described Krieger et al., 2001 ). The genotype 1b Con1 adapted transient replicon (rep PI-luc/ET) was provided by Dr. R. Bartenschlager (Lohmann et al., 2003) .
The transient genotype 1b replicon was modified for the cloning of NS5B clinical isolates by introducing the restriction enzyme sites AsiSI and SacII at the extremities of the NS5B gene. The NS5B gene from genotype 1b HCV-infected plasma was amplified and cloned into the genotype 1b transient replicon.
The transient genotype 1a replicon was constructed by replacing the non-structural region of the Con1 transient replicon by the H77 sequence, except for the first 75 amino acid residues, which remain of Con 1 origin and introducing the AsiSI site and RsrII sites at the extremities of the NS5B gene. For better replication capacity, 3 adaptive mutations were introduced (Yi and Lemon, 2004) . The NS5B gene from genotype 1a HCV-infected plasma was amplified and cloned into the genotype 1a transient replicon.
The NS5B570-BK expression vector containing an N-terminal histidine tag and a 21 amino acid deletion in the NS5B C-terminus was kindly provided by Dr. H. Overton, Roche Discovery Welwyn (Ma et al., 2005) . NS5B570-Con1 and NS5B570-Con1-S282T expression vectors containing an N-terminal histidine tag and a 21 amino acid deletion in the NS5B C-terminus were engineered. NS5B570-H77 expression vector containing a Cterminal histidine tag and a 21 amino acid deletion in the NS5B Cterminus was also constructed.
All site-directed mutants were obtained using the Quick Change site-directed mutagenesis kit following manufacturers' instructions (Stratagene, La Jolla, CA, USA) and were confirmed by double-stranded DNA sequencing.
Compounds
Recombinant human interferon alpha-2a (ROFERON, IFN-α) was prepared at Hoffmann-La Roche (Basel, Switzerland). Stocks were diluted in Dulbecco's modified Eagle's medium (DMEM), 10% (v/v) fetal bovine serum (FBS) and stored at −80°C. Compounds 2′-C-Methyl-Cytidine (2′-C-Me-C), 2′-C-MethylAdenosine (2′-C-Me-A), R1479, benzo-1, 2, 4-thiadiazine (NNI-1) and thiophene-2-carboxylic acid (NNI-2) were synthesized in Roche Palo Alto. 2′-C-Methyl-Cytidine-5′-triphosphate (2′-C-Me-CTP) was synthesized by TriLink BioTechnologies, and 3′-deoxycytidine-5′-triphosphate (3′-dCTP) was purchased from TriLink BioTechnologies (#N-3003) . Stocks of 10 mM were prepared in 100% DMSO and stored at −20°C.
Replicon cells, IC 50 and CC 50 determinations
The genotype 1b Con1 and genotype 1a H77 subgenomic replicon cell lines expressing the renilla luciferase as a reporter gene (cell lines 2209-23 and pRLucH771b75S/I, respectively) were maintained in DMEM supplemented with 10% (v/v) FBS, 50 U/ml penicillin G, 50 μg/ml streptomycin sulphate and 0.5 mg/ ml neomycin (Geneticin, Invitrogen, Carlsbad, CA) at 37°C in a 90% humidified atmosphere of 5% CO 2 (Lohmann et al., 1999) . All replicon cell lines in this study were maintained at subconfluence to ensure constant levels of replicon RNA (Pietschmann et al., 2001 ). The cured Huh-7 cell line was kindly provided by Dr. R. Bartenschlager and maintained in the same medium as above but in the absence of neomycin. Replicon cell line carrying NS5B mutation S282T (cell line clone 16) was selected as follows: 0.7 million 2209-23 replicon cells were plated in a 15-cm dish in the presence of neomycin and 2 μM of 2′-C-Me-A (20 × IC 50 ). A dish without compound was set up in parallel as a control. Culture medium was changed every 3 days and fresh 2′-C-Me-A or DMSO dilution added to the selection and control plates, respectively. After 1 week of culture, untreated and treated cells were passaged at a 1 to 5 dilution. After 4 weeks, individual cellular clones were visible on the plates that were cultured in the presence of 2′-C-Me-A. Untreated cells were continuously passaged at a 1 to 10 dilution when they reached ∼95% confluency. Cell clone 16 was expanded for further characterization. Direct sequencing of PCR products spanning the entire NS5B coding region confirmed the presence of mutation S282T.
IC 50 determinations were performed as follows: five thousand 2209-23 or three thousand pRLucH771b75S/I replicon cells were plated in 96-well plates in a total volume of 100 μl of growth media in DMEM containing 5% (v/v) FBS without neomycin. Inhibitors were added 24 h post-plating in 3-fold dilutions at a final DMSO concentration of 1% (v/v). After 3 days, cells were harvested, and replicon reduction was measured by renilla luciferase signal quantification using the renilla luciferase assay system and following manufacturer's instructions (Promega Madison, WI, USA) and/or by quantitative kinetic PCR determination of the levels of HCV replicon RNA. The levels of HCV RNA were determined using the probe 5′-TCCTGCCGAGAA-AGTATCCATCATGGCT-3′, forward 5′-GCTGCTATTGGGC-GAAGTG-3′ and reverse 5′-GCCGCCGCATTGCA-3′ primers. Probe and primer sets specific for β-actin were used as an endogenous control. All reagents for the RT-PCR were obtained from Applied Biosystems, Foster City, CA, USA. Reactions were analyzed on a 7700 Sequence Detector (PE Biosystems). IC 50 determinations using transient replicons were performed as follows: four million cured Huh-7 cells were transfected with 10 μg of in vitro transcribed genotype 1b Con1 HCV transient subgenomic replicon RNA (wild type or mutants) prepared as previously described (Lohmann et al., 2003) . After electroporation, cells were resuspended in 9.6 ml of DMEM containing 5% (v/v) FBS and plated in 48-well plate at 80,000 cells/well (in 200 μl final volume). Inhibitors were added 24 h post-transfection in 3-fold dilutions at a final DMSO concentration of 1% (v/v) and firefly luciferase reporter signal was read 72 h after addition of inhibitors using the Luciferase Assay system (Promega, Madison, WI, USA). The IC 50 values were assessed as the inhibitor concentration at which a 50% reduction in the levels of firefly luciferase reporter was observed as compared to untreated samples. For the characterization of clinical isolates cloned into the transient replicons (Con1 or H77), four million cured Huh-7 cells were transfected with 5 μg of in vitro transcribed RNA. After electroporation, cells were resuspended in 7.2 ml of DMEM containing 5% (v/v) FBS and plated in 96-well plates at 50,000 cells/well (in 100 μl final volume).
Cytotoxicity was assessed by measuring cell viability using Cell Proliferation Reagent WST-1 (Roche Applied Science, Indianapolis, IN, USA). Cells were incubated with inhibitors for 72 h as described above. WST-1 reagent was added 2 h before harvesting, and cell viability measurement was performed following manufacturer's instructions. The effect of inhibitors on the incorporation of tritiated thymidine into cellular DNA was measured using the Scintillation proximity [
3 H]-thymidine uptake assay system (Amersham Biosciences, Piscataway, NJ, USA) following manufacturer's instructions.
In vitro combination studies HCV replicon 2209-23 cells were plated as described above. Inhibitors were added at different concentrations in 3-fold dilutions at a final DMSO concentration of 1% (v/v) in a checkerboard fashion, including titrations of each of the compounds alone as reference controls. The concentrations of IFN-α used ranged from 10 to 0.04 IU/ml and from 10 to 0.04 μM for 2′-C-Me-C. The degree of interaction between two drugs was first determined using the Elion's Fractional Inhibitory Concentration (FIC) and isobologram concept (Elion et al., 1954) . IC 90 values for each inhibitor alone and in the presence of constant concentrations of the other were calculated based on the reduction of renilla luciferase reporter using the Luciferase Assay system (Promega, Madison, WI, USA). These endpoint conditions were expressed as fractions of the IC 90 for each compound alone (FIC) and used to produce isobolograms. In this study, we have adopted the following criteria: when the combination index (FIC A + FIC B ) > 1, the combination is considered antagonistic. Between 1 and 0.5, the combination is considered additive. When it is ≤0.5, the combination is considered synergistic. The data were also examined using the Pritchard and Shipman's 3-D model (MacSynergy II) (Prichard and Shipman, 1990) , where three replicate data sets were used to produce the theoretic additive surface and 95% confidence limits. Volumes above or below the theoretic additive surface were determined to indicate the degree of synergy or antagonism. Data were analyzed using Microsoft Excel.
Replicon clearance assay
HCV replicon cells were cultured in the presence of 8 μM of 2′-C-Me-C and in the absence of neomycin selection for 13 days (replicon clearance phase). Cells were passaged at a 1:3 ratio when confluent and samples were taken for HCV RNA level determination. After 13 days, the inhibitor was removed, and cells were cultured for a further 15 days in culture medium containing 0.25 mg/ml of neomycin. Levels of HCV RNA were determined using the quantitative PCR assay as described above and using the following equations: the absolute kinetic PCR cycle threshold (Ct) was obtained for the neomycin gene and for the endogenous control β-actin gene at each time point. To normalize HCV replicon to the endogenous control, dCt is calculated as dCt = (Ct Neo ) − (Ct Actin ) for each time point. The level of HCV replicon RNA is calculated as log (2^((−1)*ddCT)) (comparative Ct method, Applied Biosystems) where ddCt = (dCt (Day x) − dCt (Day 0) ). The estimated variability of the assay is typically 0.25 log and no more than 0.5 log. The TaqMan PCR reactions were performed in triplicate using 100 ng of total RNA. The limit of detection of the quantitative PCR assay is determined by the PCR cycle at which the amplification signal can be detected. The amount of HCV RNA detected after prolonged treatment with the inhibitor (Ct: 38) is close to the limit of detection (Ct: 40). Results were expressed as log RNA change compared to the HCV RNA level in untreated cells at day 0.
Selection of clonal replicons resistant to 2′-C-Me-C
For the selection of replicon cellular clones resistant to 2′-CMe-C, 0.7 million HCV replicon 2209-23 cells were plated in a 15-cm dish in the presence of 6 μM of 2′-C-Me-C and 0.5 mg/ml of neomycin. A dish without compound was set up in parallel as a control. Culture medium was changed every 3 days and fresh 2′-C-Me-C added where required. Cells were passaged at a 1 to 10 dilution twice and maintained in 6 μM for 7 weeks before increasing the concentration of 2′-C-Me-C to 12 μM. After 2 weeks, the concentration of 2′-C-Me-C was increased to 24 μM. Individual cellular clones were visible and picked 3 weeks later. Untreated cells were continuously passaged at a 1 to 10 dilution when they reached ∼95% confluency. Four cellular clones from the 2′-C-Me-C treated dish were expanded for further characterization by direct sequencing of PCR products spanning the entire non structural coding region and by determination of their susceptibility to the inhibitor. Sequencing reactions were carried out on both strands using ABI 3730 ×l DNA Analyzer. Sequences were analyzed using Sequencher and VNTI softwares. For molecular cloning purpose, NS5B amplicons were cloned into TOPO vector (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions.
Selection of replicon pools resistant to R1479
The replicon cell line 2209-23 was seeded at a density of 0.5 million cells in a T75 cm 2 flask and cultured in the presence of 0.5 mg/ml of neomycin and of increasing concentrations of R1479, starting at 1 μM and up to 60 μM. Cells were passaged at a 1 to 3 dilution when 95% confluency was reached. A parallel flask of 2209-23 cells was passaged without inhibitor as a control. Culture medium was changed every 3 days and fresh compound added where required. Replicon cells were characterized by determining their sensitivity to R1479 and by direct sequencing of PCR products spanning the entire NS5B coding region.
HCV polymerase assay
The inhibition potency of 2′-C-Me-CTP on the RNAdependent RNA polymerase (RdRp) activity of recombinant NS5B570-BK, NS5B570-Con1 and NS5B570-H77 proteins was measured as the incorporation of radiolabeled nucleotide monophosphate into acid-insoluble RNA products. The method was used as previously described (Ma et al., 2005) with some modifications, using either cIRES RNA template (genotype 1a assay conditions) or Poly I RNA template (PI assay conditions). Briefly, IC 50 determinations, measured under genotype 1a assay conditions, were carried out using 200 nM of in vitro transcribed cIRES RNA template derived from the 3′ end of the negative strand RNA genome , 1 μCi of tritiated UTP (42 Ci/mmol), 1 mM ATP, 1 mM GTP, 1 μM CTP, 1× TMDN buffer (40 mM Tris-HCl pH 8.0, 4 mM MgCl 2 , 4 mM DTT, 40 mM NaCl) and 200 nM enzyme. The IC 50 determinations measured under PI assay conditions contained 8 μg/ml Poly I RNA (Yamasa Co.), 4 μg/ml oligo C 16 (Dharmacon), 1 μCi of titrated CTP (25 Ci/mmol, corresponding to a final CTP concentration of 0.8 μM), 1× TMDN buffer and 200 nM enzyme. In both assay conditions, 5 μl of serially diluted inhibitor was added to each reaction. The inhibition potency of 2′-C-Me-CTP on the RdRp activity of NS5B570-Con1-S282T was determined under genotype 1b assay conditions as previously described (Klumpp et al., 2006) with the following modifications: each reaction mixture contained 200 nM cIRES RNA template, 1μCi of tritiated UTP (42 Ci/mmol), and 1× TMDN buffer. NS5B570-BK and NS5B570-Con1 enzymes were used as controls and tested under the same assay conditions. The final reaction volume was 50 μl under all assay conditions. All reactions contained a final 10% DMSO.
HCV replicase complex assay
Preparation of membrane-associated cytoplasmic replicase complexes (CRC) from replicon cells was described previously (Ma et al., 2005) . In vitro replicase assay and RNA product analysis were performed as previously described except that 5 μl of sCRC (2.5 × 10 6 cell equivalent) was used in the reactions (Ma et al., 2005) . RNA synthesis activity of the replicase complex in the presence of inhibitor was expressed as a percentage of the RNA synthesis activity in the absence of inhibitor. The IC 50 value was determined by GraphPad Prism software using the four parameter logistic equation Y = %Min + (%Max − %Min)/ (1 + 10^(logIC 50 − X)*Hillslope), in which "Y" corresponds to the relative enzyme activity (in %), "%Min" is the residual relative enzymatic activity at the highest compound concentration, "% Max" is the relative enzymatic activity at the lowest compound concentration, X is the logarithm of inhibitor concentration.
Western blotting detection of NS5B
Serial dilutions of the recombinant NS5B570-BK and membrane fractions from replicon cells were resolved by SDS-PAGE and transferred to PVDF membranes. The membranes were probed with a rabbit antiserum developed against NS5B570-BK. The Western blotting detection was performed using a horse peroxidase conjugated goat anti-rabbit IgG secondary antibody (Santa Cruz Biotechnologies #SC-2030) and ECLplus substrate (Amersham Biosciences #RPN2132). Chemifluorescence signal detection was performed using a Typhoon 9400 scanner (Amersham Biosciences) and density volumes of NS5B bands quantified using ImageQuant software.
